GLUE

Monte Rosa Therapeutics, Inc. is a biotechnology company developing molecular glue degrader (MGD) medicines for targeted protein degradation. The company's proprietary QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform enables the discovery of small molecules that induce degradation of disease-causing proteins. Monte Rosa's lead program, MRT-2359, targets GSPT1 degradation for the treatment of MYC-driven cancers and is currently in clinical development. The company is advancing additional programs targeting oncology and immunology indications using its protein degradation technology. Monte Rosa's approach represents a novel therapeutic modality that goes beyond traditional enzyme inhibition by eliminating entire disease-relevant proteins. The company has established strategic collaborations with pharmaceutical partners to expand its pipeline and validate its technology platform across multiple therapeutic areas.